

On November 21, 2019, Amgen Inc. acquired the Otezla® brand from Celgene, a Bristol Myers Squibb™ company. As a result of this acquisition Amgen introduced new NDCs for Otezla® on July 1, 2020. The new NDCs do not represent any change in form, strength or product composition of Otezla®.

The table below reflects the old and new NDCs for Otezla®. Please note that each new NDC is a *replacement* for an old NDC, and thus each pair of old/new NDCs is treated as if it were the *same* NDC for purposes of pricing and purchasing from Amgen through the 340B program.

Old NDC	Description	New NDC
59572-0631-06	Otezla® 30mg tab x60	55513-0137-60
59572-0632-55	Otezla® 10/20/30mg tab x55	55513-0369-55

340B Inventory Replenishment:

Because the new NDCs are, in fact, the same product (drug, dose, formulation, or volume) with the same 340B price as the corresponding old NDCs, Amgen believes that a covered entity utilizing a 340B inventory replenishment model may count accumulations of the old NDCs toward replenishment of equal quantities of the corresponding new NDC (see above table).

Any questions regarding this matter can be directed to 340Brelations@amgen.com.